1 active not recruiting, 1 completed. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow Epidermolysis Bullosa Simplex: new trials by email Literature Review of Epidermolysis Bullosa Simplex trials Research Report on Epidermolysis Bullosa Simplex
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) AC-203, Vehicle - Generalized Epidermolysis Bullosa Simplex | Phase 2 / Phase 3 | Active not recruiting | TWi Biotechnology, Inc. | 80 | 2024-04-04 | 2026-07-09 |
| Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex Botulinic toxin, Placebo - Epidermolysis Bullosa Simplex | Phase 2 / Phase 3 | Completed | University Hospital, Toulouse | 18 | 2018-06-14 | 2026-09-21 |
Blister (1)
Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Epidermolysis Bullosa (2) · Genetic Diseases, Inborn (2) · Skin Abnormalities (2) · Skin Diseases (2) · Skin Diseases, Genetic (2) · Skin Diseases, Vesiculobullous (2) · Skin and Connective Tissue Diseases (2) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1)
Drugs, Investigational (1) · abobotulinumtoxinA (1) · diacerein (1)
TWi Biotechnology, Inc. (1) · University Hospital, Toulouse (1)
Australia (1) · Austria (1) · Belgium (1) · China (1) · France (1) · Greece (1) · India (1) · Ireland (1) · Israel (1) · Italy (1) · Malaysia (1) · Philippines (1) · Poland (1) · South Korea (1) · Spain (1)
Juliette Mazereeuw-Hautier, MD (1)
2017 (1)